Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine, Obinutuzumab and Venetoclax in Untreated Mantle Cell Lymphoma
NCT03872180Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, bendamustine and obinutuzumab in mantle cell lymphoma (MCL), sponsored by Emory University. Primary endpoint: Complete Response Rate at 2.5 years. Started Apr 2019; status: active, not recruiting.
02
Drugs
venetoclaxbendamustineobinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03872180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872180.